
Stromedix secures broad patent coverage for lead program
MORE (PDF) >
Stromedix receives orphan drug designation for STX-100 in chronic allograft nephropathy
MORE (PDF) >
Stromedix raises $25 million in a Series B financing round
MORE (PDF) >

Mass High Tech
GO >
Xconomy.com
GO >
In Vivo Blog
GO >
Biocentury
GO >

Corporate Factsheet
Download our Corporate Factsheet for information on who we are and what we do.
DOWNLOAD (PDF) >

Follow Stromedix on Twitter
GO >
|
|
 
STX-100 is Stromedix's first clinical candidate and is being developed for the treatment of chronic allograft dysfunction in kidney transplant recipients.
 |
Humanized monoclonal antibody to integrin αvβ6 |
 |
Completed phase 1 clinical testing in 2008 |
 |
Provides localized, injury-specific inhibition of TGF-β activation
|
 |
Significant anti-fibrotic activity in preclinical models of lung, kidney and liver disease |
 |
Broad therapeutic utility in chronic organ failure, acute organ failure and cancer |
|